Media stories about Eiger Biopharmaceuticals (NASDAQ:EIGR) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Eiger Biopharmaceuticals earned a news impact score of 0.04 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.208668379806 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of equities analysts have recently weighed in on EIGR shares. Zacks Investment Research upgraded Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a report on Monday, October 16th. Oppenheimer reissued a “buy” rating and set a $34.00 target price on shares of Eiger Biopharmaceuticals in a research note on Monday, September 25th. Wedbush reissued a “buy” rating on shares of Eiger Biopharmaceuticals in a research note on Wednesday, October 25th. Roth Capital assumed coverage on Eiger Biopharmaceuticals in a research note on Thursday, October 19th. They set a “buy” rating and a $35.00 target price on the stock. Finally, ValuEngine raised Eiger Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $30.43.

Eiger Biopharmaceuticals (EIGR) opened at $12.10 on Friday. Eiger Biopharmaceuticals has a 12 month low of $6.10 and a 12 month high of $13.95. The company has a quick ratio of 5.78, a current ratio of 5.78 and a debt-to-equity ratio of 1.19.

Eiger Biopharmaceuticals (NASDAQ:EIGR) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. equities analysts predict that Eiger Biopharmaceuticals will post -4.8 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at

Eiger Biopharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger Biopharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.